XELOX和OLF化疗方案治疗K-ras基因突变型老年晚期大肠癌的疗效分析

Efficacy of XELOX and OLF chemotherapy in advanced colorectal cancer patients with KRAS gene mutations

摘要:

目的  比较分析K-ras基因突变型老年晚期大肠癌患者接受奥沙利铂联合卡培他滨（XELOX）和奥沙利铂联合氟尿嘧啶（OLF）化疗方案的疗效。方法  分析2009年1月-2012年8月该院收治的经基因分析确诊为K-ras基因突变型晚期大肠癌病例，共106例。其中接受XELOX化疗者56例，接受OLF化疗者50例，并比较分析两组接受化疗后发生毒副反应、客观缓解率、疾病控制率、无进展生存期、总生存期的差异。结果  OLF组骨髓抑制、恶心呕吐、静脉炎、心脏毒性的发生率高于XELOX组，而腹泻的发生率XELOX组要明显高于OLF组，在口腔炎及神经毒性的发生率上，两组差异无统计学意义。两组客观缓解率、疾病控制率、无进展生存期和总生存期差异无统计学意义。结论  XELOX治疗K-ras基因突变型老年晚期结肠癌具一定疗效，相对安全，可提高患者的生存质量。

Abstract:

Objective To investigate the clinical effect of XELOX and OLF chemotherapy in advanced colorectal cancer patients with KRAS gene mutations. Methods KRAS mutations were found in 106 colorectal cancer patients in our hospital from January 2009 to August 2012. Among them, 56 cases received XELOX chemotherapy, 50 cases received OLF chemotherapy. The toxic and side effects, objective response rate, disease control rate, progression-free survival, and overall survival were compared between the two groups after chemotherapy. Results The incidences of bone marrow suppression, nausea and vomiting, phlebitis, cardio-toxicity in the OLF group were higher than those in the XELOX group, while the incidence of diarrhea in the XELOX group was significantly higher than that in the OLF group. There was no significant difference in the incidence of stomatitis or neurotoxicity, objective response rate, disease control rate, progression-free survival or overall survival between the two groups. Conclusions Compared with OLF, XELOX appears to be a relatively safe and effective chemotherapy and can improve the patient's quality of life.